Saturday, November 2, 2024
HomeTagsDisease-free survival

disease-free survival

IMFINZI-based treatment before and after surgery reduced the risk of disease recurrence, progression events or death by 32% in resectable non-small cell lung cancer...

Positive results from the AEGEAN Phase III trial showed that treatment with AstraZeneca’s IMFINZI in combination with neoadjuvant chemotherapy before surgery and as adjuvant monotherapy...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics